Response Pharmaceuticals | Weight Management

top of page

Targeted Solutions for Weight Management and Metabolic Health

Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists

February 06, 2025

Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week

October 17, 2024

Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial

April 23, 2024

Read more

Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002

August 17, 2023

Read more

Response Pharmaceuticals Closes Series A Financing

November 21, 2022

Read more

bottom of page